These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 24977435)

  • 61. Role of HLA-B*5101 binding nonamer peptides in formation of the HLA-Bw4 public epitope.
    Takamiya Y; Sakaguchi T; Miwa K; Takiguchi M
    Int Immunol; 1996 Jul; 8(7):1027-34. PubMed ID: 8757948
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Analysis of binding of KIR3DS1*014 to HLA suggests distinct evolutionary history of KIR3DS1.
    O'Connor GM; Yamada E; Rampersaud A; Thomas R; Carrington M; McVicar DW
    J Immunol; 2011 Sep; 187(5):2162-71. PubMed ID: 21804024
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57.
    Kamya P; Boulet S; Tsoukas CM; Routy JP; Thomas R; Côté P; Boulassel MR; Baril JG; Kovacs C; Migueles SA; Connors M; Suscovich TJ; Brander C; Tremblay CL; Bernard N;
    J Virol; 2011 Jun; 85(12):5949-60. PubMed ID: 21471235
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Heterogeneous phenotypes of expression of the NKB1 natural killer cell class I receptor among individuals of different human histocompatibility leukocyte antigens types appear genetically regulated, but not linked to major histocompatibililty complex haplotype.
    Gumperz JE; Valiante NM; Parham P; Lanier LL; Tyan D
    J Exp Med; 1996 Apr; 183(4):1817-27. PubMed ID: 8666938
    [TBL] [Abstract][Full Text] [Related]  

  • 65. KIR3DS1-Specific D0 Domain Polymorphisms Disrupt KIR3DL1 Surface Expression and HLA Binding.
    Mulrooney TJ; Zhang AC; Goldgur Y; Boudreau JE; Hsu KC
    J Immunol; 2015 Aug; 195(3):1242-50. PubMed ID: 26109640
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effect of HLA Bw4/Bw6 compatibility on platelet transfusion responses of refractory thrombocytopenic patients.
    McElligott MC; Menitove JE; Duquesnoy RJ; Hunter JB; Aster RH
    Blood; 1982 May; 59(5):971-5. PubMed ID: 6951616
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The role of the amino acids associated with the HLA-Bw4/Bw6 epitope in peptide binding to HLA-B5, B35 CREG molecules.
    Sobao Y; Miwa K; Takiguchi M
    Immunogenetics; 1999 Aug; 49(9):819-22. PubMed ID: 10398811
    [No Abstract]   [Full Text] [Related]  

  • 68. Degenerate recognition of MHC class I molecules with Bw4 and Bw6 motifs by a killer cell Ig-like receptor 3DL expressed by macaque NK cells.
    Maloveste SM; Chen D; Gostick E; Vivian JP; Plishka RJ; Iyengar R; Kruthers RL; Buckler-White A; Brooks AG; Rossjohn J; Price DA; Lafont BA
    J Immunol; 2012 Nov; 189(9):4338-48. PubMed ID: 23041569
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prediction of KIR3DL1/Human Leukocyte Antigen binding.
    Maiers M; Louzoun Y; Pymm P; Vivian JP; Rossjohn J; Brooks AG; Saunders PM
    bioRxiv; 2024 May; ():. PubMed ID: 38746109
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Inhibitory Killer Immunoglobulin-like Receptors to self HLA-B and HLA-C ligands contribute differentially to Natural Killer cell functional potential in HIV infected slow progressors.
    Kamya P; Tallon B; Melendez-Pena C; Parsons MS; Migueles SA; Connors M; Miconiatis S; Song R; Boulet S; Bruneau J; Tremblay CL; Bernard NF;
    Clin Immunol; 2012 Jun; 143(3):246-55. PubMed ID: 22445844
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The Bw4/Bw6 difference between HLA-B*0802 and HLA-B*0801 changes the peptides endogenously bound and the stimulation of alloreactive T cells.
    Arnett KL; Huang W; Valiante NM; Barber LD; Parham P
    Immunogenetics; 1998 Jun; 48(1):56-61. PubMed ID: 9601944
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Serological demonstration of HLA-Bw4/Bw6 epitopes on hybrid molecules between HLA-B35 and HLA-B51.
    Sekimata M; Hayashi H; Nakayama S; Kano K; Takiguchi M
    Immunogenetics; 1989; 30(3):229-31. PubMed ID: 2476390
    [No Abstract]   [Full Text] [Related]  

  • 73. HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.
    Erbe AK; Wang W; Reville PK; Carmichael L; Kim K; Mendonca EA; Song Y; Hank JA; London WB; Naranjo A; Hong F; Hogarty MD; Maris JM; Park JR; Ozkaynak MF; Miller JS; Gilman AL; Kahl B; Yu AL; Sondel PM
    Front Immunol; 2017; 8():675. PubMed ID: 28659916
    [TBL] [Abstract][Full Text] [Related]  

  • 74. HLA alleles determine differences in human natural killer cell responsiveness and potency.
    Kim S; Sunwoo JB; Yang L; Choi T; Song YJ; French AR; Vlahiotis A; Piccirillo JF; Cella M; Colonna M; Mohanakumar T; Hsu KC; Dupont B; Yokoyama WM
    Proc Natl Acad Sci U S A; 2008 Feb; 105(8):3053-8. PubMed ID: 18287063
    [TBL] [Abstract][Full Text] [Related]  

  • 75. NK cell natural cytotoxicity and IFN-gamma production are not always coordinately regulated: engagement of DX9 KIR+ NK cells by HLA-B7 variants and target cells.
    Kurago ZB; Lutz CT; Smith KD; Colonna M
    J Immunol; 1998 Feb; 160(4):1573-80. PubMed ID: 9469412
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Phenotypical and functional profiles of natural killer cells exhibiting matrix metalloproteinase-mediated CD16 cleavage after anti-HIV antibody-dependent activation.
    Tang CC; Isitman G; Bruneau J; Tremblay C; Bernard NF; Kent SJ; Parsons MS
    Clin Exp Immunol; 2015 Aug; 181(2):275-85. PubMed ID: 25644502
    [TBL] [Abstract][Full Text] [Related]  

  • 77. HIV protective KIR3DL1/S1-HLA-B genotypes influence NK cell-mediated inhibition of HIV replication in autologous CD4 targets.
    Song R; Lisovsky I; Lebouché B; Routy JP; Bruneau J; Bernard NF
    PLoS Pathog; 2014 Jan; 10(1):e1003867. PubMed ID: 24453969
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The D0 domain of KIR3D acts as a major histocompatibility complex class I binding enhancer.
    Khakoo SI; Geller R; Shin S; Jenkins JA; Parham P
    J Exp Med; 2002 Oct; 196(7):911-21. PubMed ID: 12370253
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Under representation of the inhibitory KIR3DL1 molecule and the KIR3DL1+/BW4+ complex in HIV exposed seronegative individuals.
    Guerini FR; Lo Caputo S; Gori A; Bandera A; Mazzotta F; Uglietti A; Zanzottera M; Maserati R; Clerici M
    J Infect Dis; 2011 May; 203(9):1235-9. PubMed ID: 21398398
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Putative role of KIR3DL1/3DS1 alleles and HLA-Bw4 ligands with end stage renal disease and long term renal allograft survival.
    Prakash S; Sarangi AN; Alam S; Sonawane A; Sharma RK; Agrawal S
    Gene; 2017 Dec; 637():219-229. PubMed ID: 28942035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.